KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Debt: 2009-2024

Historic Total Debt for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Jun 2024 value amounting to $494.8 million.

  • Biomarin Pharmaceutical's Total Debt was N/A to $494.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $494.8 million, marking a year-over-year change of. This contributed to the annual value of $493.9 million for FY2023, which is 3001.27% up from last year.
  • As of Q2 2024, Biomarin Pharmaceutical's Total Debt stood at $494.8 million, which was up 0.10% from $494.4 million recorded in Q1 2024.
  • In the past 5 years, Biomarin Pharmaceutical's Total Debt registered a high of $494.8 million during Q2 2024, and its lowest value of $15.9 million during Q4 2022.
  • Its 3-year average for Total Debt is $264.3 million, with a median of $278.7 million in 2022.
  • In the last 5 years, Biomarin Pharmaceutical's Total Debt surged by 3,642.90% in 2020 and then crashed by 91.58% in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Total Debt (Quarterly) stood at $374.3 million in 2020, then slumped by 87.12% to $48.2 million in 2021, then slumped by 66.98% to $15.9 million in 2022, then surged by 3,001.27% to $493.9 million in 2023, then reached $494.8 million in 2024.
  • Its Total Debt stands at $494.8 million for Q2 2024, versus $494.4 million for Q1 2024 and $493.9 million for Q4 2023.